Synthesis of glucocorticoid-induced leucine zipper (GILZ) by macrophages: An anti-inflammatory and immunosuppressive mechanism shared by glucocorticoids and IL-10

Blood

Volumn 101, Issue 2, 2003, Pages 729-738

  Berrebi, Dominique ^a,b,c   Bruscoli, Stefano ^a,b,c   Cohen, Nicolas ^a,b,c   Foussat, Arnaud ^a,b,c   Migliorati, Graziella ^a,b,c   Bouchet Delbos, Laurence ^a,b,c   Maillot, Marie Christine ^a,b,c   Portier, Alain ^a,b,c   Couderc, Jacques ^a,b,c   Galanaud, Pierre ^a,b,c   Peuchmaur, Michel ^a,b,c   Riccardi, Carlo ^a,b,c   Emilie, Dominique ^a,b,c  

^a INSERM   (France)

^b HÔPITAL ROBERT DEBRÉ   (France)

^c UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GLUCOCORTICOID; INTERLEUKIN 10; LEUCINE ZIPPER PROTEIN; LIPOPOLYSACCHARIDE; MACROPHAGE INFLAMMATORY PROTEIN 1; TOLL LIKE RECEPTOR 2;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BURKITT LYMPHOMA; CONTROLLED STUDY; CROHN DISEASE; DOWN REGULATION; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNE SYSTEM; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN SYNTHESIS; TUBERCULOSIS;

EID: 0037438590     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-02-0538     Document Type: Article

References (56)

1. van de Stolpe A, Caldenhoven E, Stade BG, et al. 12-0-Tetradecanoylphorbol-13-acetate and tumor necrosis factor α-mediated induction of intercellular adhesion molecule 1 is inhibited by dexamethasone. J Biol Chem. 1994;269 6185-6192.
2. Schwiebert LM, Schleimer RP, Radka SF, Ono SJ. Modulation of MHC class II expression in human cells by dexamethasone. Cell Immunol, 1995;165:12-19.
3. TailorA, Des AM, Getting SJ, Flower RJ, Perretti M. Subacute treatment of rats with dexamethasone reduces ICAM-1 levels on circulating monocytes. Biochem Biophys Res Commun, 1997;231;675-678.
4. Goppelt-Struebe M, Schaefer D, Habenicht AJ. Differential regulation of cyclo-oxygenase-2 and 5-lipoxygenase activating protein (FLAP) expression by glucocorticoids in monocytic cells. Br J Pharmacol. 1997;122:619-624.
5. De Vera ME, Taylor BS, Wang Q, Shapiro RA, Billiar TR, Geller DA. Dexamethasone suppresses iNOS gene expression by upregulating I-kappa B alpha and inhibiting NF-kappa B. Am J Physiol. 1997;273:1290-1296.
6. Girndt M, Sester U, Kaul H, Hunger F, Kohler H. Glucocorticoids inhibit activation dependent expression of costimulatory molecule B7-1 in human monocytes. Transplantation. 1998;66:370-375.
7. Wiegers GJ, Reul JMHM. Induction of cytokine receptors by glucocorticoids: functional and pathological significance. Trends Pharmacol Sci. 1998;19:317-321.
8. Steer JM, Kroeger KM, Abraham LJ, Joyce DA. Glucocorticoids suppress tumor necrosis factor-α expression by human monocytic THP-1 cells by suppressing transactivation through adjacent NF-κB and c-jun activating transcription factor 2 binding sites in the promotor. J Biol Chem. 2000;275:18432-18440.
9. Marfaing-Koka A, Maravic M, Humbert M, Galanaud P, Emilie D. Contrasting effects of IL-4, IL-10 and corticosteroids on RANTES production by human monocytes. Int Immunol. 1996;8:1587-1594.
10. Rovai LE, Herschman HR, Smith JB. The murine neutrophil-chemoattractant chemokines LIX, KC, and MIP-2 have distinct induction kinetics, tissue distributions, and tissue specific sensitivities to glucocorticoid regulation in endotoxemia. J Leukoc Biol. 1998;64:494-502.
11. Mehundate K, Al-Daccak R, Schall TJ, Mourad W. Induction of chemokine gene expression by major histocompatibility complex class II ligands in human fibroblast like synoviocytes: differential regulation by interleukin-4 and dexamethasone. J Biol Chem. 1994;269:32063-32069.
12. Berkman N, Jose PJ, Williams TJ, Schall TJ, Barnes PJ, Chung KF. Corticosteroid inhibition of macrophage inflammatory protein-1 alpha in human monocytes and alveolar macrophages. Am J Physiol. 1995;269:443-452.
13. Mukaida N, Zachariae CCO, Gusella GL, Matsuschima K. Dexamethasone inhibits the induction of monocyte chemotactic-activating factor production by IL-1 or tumor necrosis factor. J Immunol. 1991;146:1212-1215.
14. Stordeur P, Goldman M. Interleukin-10 as a key regulator of inflammation and stress response. In: Bona CA, Revillard J-P, eds. Cytokines and cytokine receptors. Amsterdam, The Netherlands: Harwood Academic Publishers; 2000:229-247.
15. Karin M. New twists in gene regulation by glucocorticoid receptor: is DNA binding dispensable? Cell. 1998;93:487-490.
16. Barnes PJ, Karin M. Nuclear factor-kB: a pivotal transcription factor in chronic inflammatory disease. N Engl J Med. 1997;336:1066-1071.
17. Aderem A, Ulevitch RJ. Toll-like receptors in the induction of the innate immune response. Nature. 2000;406:782-787.
18. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol. 2001;2:675-680.
19. Golenbock DT, Fenton MJ. Extolling the diversity of bacterial endotoxins. Nat Immunol. 2001;2:286-288.
20. Zhang G, Ghosh S. Toll-like receptor-mediated NF-κB activation: a phylogenetically conserved paradigm in innate immunity. J Clin Invest. 2001;107:13-19.
21. Wagner H. Toll meets bacterial CpG-DNA. Immunity. 2001;14:499-502.
22. D'Adamio F, Zollo O, Moraca R, et al. A new dexamethasone-induced gene of the leucine zipper family protects T lymphocytes from TCR/CD3 activated cell death. Immunity. 1997;7:803-812.
23. Cannarile L, Zollo O, D'Adamio F, et al. Cloning, chromosomal assignment and tissue distribution of human GILZ, a glucocorticoid hormoneinduced gene. Cell Death Diff. 2001;8:201-203.
24. Mittelstadt PR, Ashwell JD. Inhibition of AP-1 by the glucocorticoid-inducible protein GILZ. J Biol Chem. 2001;276:29603-29610.
25. Ayroldi E, Migliorati G, Bruscoli S, et al. Modulation of T-cell activation by the glucocorticoidinduced leucine zipper factor via inhibition of nuclear factor kB. Blood. 2001;98:743-753.
26. Millet I, Phillips RJ, Sherwin RS, et al. Inhibition of NF-κB activity and enhancement of apoptosis by the neuropeptide calcitonin gene-related peptide. J Biol Chem. 2000;275:15114-15121.
27. Ayroldi E, Migliorati G, Cannarile L, Moraca R, Delfino DV, Riccardi C. CD2 rescues T cells from T cell receptor/CD3 apoptosis: a role for the Fas/Fas-L system. Blood. 1997;89:3717-3726.
28. Estaquier J, Idziorek T, Zou W, et al. T helper type 1/T helper type 2 cytokines and T cell death: preventive effect of interleukin12 on activation induced and CD95 (FAS/APO-1) mediated apoptosis of CD4+ T cells from human immunodeficiency virus-infected persons. J Exp Med. 1995;182:1759-1767.
29. Foussat A, Coulomb-L'Hermine A, Gosling J, et al. Fractalkine receptor expression by T lymphocyte subpopulations and in vivo production of fractalkine in human. Eur J Immunol. 2000;30:87-97.
30. Groux H, Cottrez F, Rouleau M, et al. A transgenic model to analyze the immunoregulatory role of IL-10 secreted by antigen-presenting cells. J Immunol. 1999;162:1723-1729.
31. Glynne R Ghandour G, Rayner J, Mack DH, Goodnow CC. B-lymphocyte quiescence, tolerance and activation as viewed by global gene expression profiling on microarrays. Immunol Rev. 2000;176:216-246.
32. Génin P, Algarté M, Roof P, Lin R, Hiscott J. Regulation of RANTES chemokine gene expression requires cooperativity between NF-κB and IFN-regulatory factor transcription factors. J Immunol. 2000;164:5352-5361.
33. Chomarat P, Banchereau J. An update on interleukin-4 and its receptor. Eur Cytokine Netw. 1997;8:333-344.
34. Minty A, Chalon P, Derocq JM, et al. Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses. Nature. 1993;362:248-250.
35. Zurawski G, de Vries JE. Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cells. Immunol Today. 1994;15:19-26.
36. Cosentino G, Soprana E, Thienes CP, Siccardi AG, Viale G, Vercelli D. IL-13 down-regulates CD14 expression and TNF-α secretion in normal human monocytes. J Immunol. 1995;155:3145-3151.
37. Muchamel T, Menon S, Pisacane P, Howard MC, Cockayne DA. IL-13 protects mice from lipopolysaccharide-induced lethal endotoxemia. J Immunol. 1997;158:2898-2903.
38. Manna SK, Aggarwal BB. IL-13 suppresses TNF-induced activation of nuclear factor-kappa B, activation protein-1, and apoptosis. J Immunol. 1998;161:2863-2872.
39. Mantovani A, Gray PA, Van Damme J, Sozzani S. Macrophage-derived chemokine (MDC). J Leukoc Biol. 2000;68:400-404.
40. Powell JD, Ragheb JA, Kitagawa-Sakakida S, Schwartz RH. Molecular regulation of interleukin-2 expression by CD28 co-stimulation and anergy. Immunol Rev. 1998;165:287-300.
41. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245-252.
42. Liu Z, Geboes K, Hellings P, et al. B7 interactions with CD28 and CTLA-4 control tolerance or induction of mucosal inflammation in chronic experimental colitis. J Immunol. 2001;167:1830-1838.
43. Hawiger D, Inaba K, Dorsett Y, et al. Dendritic cells induce peripheral unresponsiveness under steady state conditions in vivo. J Exp Med. 2001;194:769-779.
44. Albert ML, Jegathesan M, Darnell RB. Dendritic cell maturation is required for the cross-tolerization of CD8+ T cells. Nature Immunol. 2001;2:1010-1017.
45. Shortman K, Heath WR. Immunity or tolerance? That is the question for dendritic cells. Nat Immunol. 2001;2:988-989,
46. Muzio M, Bosisio D, Polentarutti N, et al. Differential expression and regulation of toll-like receptors (TLR) in human leukocytes: selective expression of TLR3 in dendritic cells. J Immunol. 2000;164:5998-6004.
47. Devergne O, Marfaing-Koka A, Schall TJ, et al. Production of the RANTES chemokine in delayed type hypersensitivity reactions: involvement of macrophages and endothelial cells. J Exp Med. 1994;179:1689-1694.
48. Chensue SW, Warmington KS, Allenspach EJ, et al. Differential expression and cross-regulatory function of RANTES during mycobacterial (type 1) and schistosomal (type 2) antigen-elicited granulomatous inflammation. J Immunol. 1999;163:165-173.
49. Schnare M, Barton GM, Czopik Holt A, Takeda K, Akira A, Medzhitov R. Toll-like receptors control activation of adaptive immune responses. Nat Immunol. 2001;2:947-950.
50. Castro AG, Neighbors M, Hurst SD, et al. Anti-interleukin-10 receptor monoclonal antibody is an adjuvant for T helper cell type 1 responses to soluble antigen only in the presence of lipopolysaccharide. J Exp Med. 2000;192:1529-1534.
51. Todd JA. Tackling common disease. Nature. 2001;411:537-539.
52. Voll RE, Hermann M, Roth EA, Stach C, Kalden JR, Girkontaite I. Immunosuppressive effects of apoptotic cells. Nature. 1997;390:350-351.
53. Ferguson TA, Green DA. T cells are just dying to accept grafts. Nat Med. 1999;5:1231-1232.
54. Sica A, Saccani A, Bottazzi B, et al. Autocrine production of IL-10 mediates defective IL-12 production and NF-κB activation in tumor-associated macrophages. J Immunol. 2000;164:762-767.
55. Steinbrink K, Jonuleit H, Müller G, Schuler G, Knop J, Enk A. Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8+ T cells resulting in a failure to lyse tumor cells. Blood. 1999;93:1634-1642.
56. Brown RS, Pope B, Murray A, et al. Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-β1 and interleukin-10. Blood. 2001;98:2992-2998.